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What is the key question?  
Can gene sequencing improve diagnosis of the inherited respiratory condition primary ciliary 
dyskinesia in patients with unclear clinical diagnostic investigations? 
 
What is the bottom line?  
CCDC103 p.His154Pro missense mutations cause up to 20% PCD cases in UK South Asian 
populations but diagnosis can be difficult in this group using standard clinical diagnostic tests 
because results are often normal; we therefore propose that genetic analysis is an essential 
part of the diagnostic algorithm to complement standard clinical tests to improve diagnostic 
accuracy. 
 
Why read on?  
Patients with primary ciliary dyskinesia may be missed using current pathology-based 
diagnostic protocols therefore genetic screening can provide valuable support in obtaining a 
definitive diagnosis. 
 
For Twitter: 140 character conclusion:  
Diagnosis can be difficult in PCD with CCDC103 p.His154Pro mutations and genetic testing 
is essential in the high-risk UK South Asian community.   
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ABSTRACT  
 
Rationale: Primary ciliary dyskinesia is a genetically heterogeneous condition characterised 
by progressive lung disease arising from abnormal cilia function. Approximately half of 
patients have situs inversus. The estimated prevalence of primary ciliary dyskinesia in the UK 
South Asian population is 1:2,265. Early, accurate diagnosis is key to implementing 
appropriate management but clinical diagnostic tests can be equivocal.  
Objectives: To determine the importance of genetic screening for primary ciliary dyskinesia  
in a UK South Asian population with a typical clinical phenotype, where standard testing is 
inconclusive.  
Methods: Next-generation sequencing was used to screen 86 South Asian patients who had a 
clinical history consistent with primary ciliary dyskinesia. The effect of a CCDC103 
p.His154Pro missense variant compared to other dynein arm-associated gene mutations on 
diagnostic/phenotypic variability was tested. CCDC103 p.His154Pro variant pathogenicity 
was assessed by oligomerisation assay. 
Results: Sixteen of 86 (19%) patients carried a homozygous CCDC103 p.His154Pro mutation 
which was found to disrupt protein oligomerisation. Variable diagnostic test results were 
obtained including normal nasal nitric oxide levels, normal ciliary beat pattern and frequency 
and a spectrum of partial and normal dynein arm retention. Fifteen (94%) patients or their 
sibling(s) had situs inversus suggesting CCDC103 p.His154Pro patients without situs inversus 
are missed. 
Conclusions: The CCDC103 p.His154Pro mutation is more prevalent than previously 
thought in the South Asian community and causes primary ciliary dyskinesia that can be 
difficult to diagnose using pathology-based clinical tests. Genetic testing is critical when there 
is a strong clinical phenotype with inconclusive standard diagnostic tests.  
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INTRODUCTION 
 
Primary ciliary dyskinesia (PCD; OMIM: 244400) is an inherited disorder affecting motile 
cilia. Patients usually present with a history of neonatal respiratory distress and suffer from 
lifelong symptoms of chronic wet cough and rhinitis. Recurrent chest infections ultimately 
lead to bronchiectasis and a progressive decline in lung function. 1 Approximately half of 
patients have situs inversus and other situs abnormalities, due to ciliary dysmotility in the 
embryonic node. 2 Fertility can also be affected by defective cilia in the fallopian tubes and 
non-motile sperm tail flagella.  
 
The estimated prevalence of PCD in the UK is 1:15,000, but as high as 1:2,265 in the UK 
South Asian population. 1 3 Early diagnosis is important to maintain lung function, and 
appropriately treat symptoms to reduce morbidity and mortality. 4 Diagnosis can be complex 
and requires a combination of tests for cilia functional and ultrastructural defects. 5 6 PCD is 
caused by mutations in genes encoding proteins conferring structural stability to the cilia and 
governing ciliogenesis. It is genetically heterogeneous with >200 individual mutations in 
more than 30 genes known to cause PCD. To date these account for approximately 65% of 
cases.1 7-11 UK Genetic Testing Network approved tests are offered in two centres 
(http://www.labs.gosh.nhs.uk/media/764464/ciliopathies_v8.pdf). 12 
 
CCDC103 mutations were first reported, in 2012, in patients with dynein arm loss and a 
typical clinical PCD phenotype. 13 CCDC103 is an oligomeric coiled-coil domain protein that 
is found tightly bound to the ciliary axoneme where it is thought to help facilitate ciliary 
motility by participating in attachment of the dynein arms to the axoneme. The protein was 
found to stabilize cytoplasmic microtubules against cold depolymerization in an in vitro 
assay. 13 A missense variant previously identified in CCDC103 to cause a single amino acid 
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change to the protein, p.His154Pro (rs145457535) was previously described as a 
hypomorphic mutation since mutant p.His154Pro CCDC103 induced intermediate partially 
rescued disease phenotypes when expressed in a zebrafish CCDC103-null model, suggesting 
some protein function was retained. 13  In cilia from p.His154Pro-positive patients some cilia 
showed a partial dynein arm defect with the outer dynein arms (ODA) at least partially 
assembled, compared to loss-of-function CCDC103 mutations causing complete ODA loss. In 
agreement with this, loss-of-function CCDC103 mutation patients had largely static cilia, 
whilst patients carrying a homozygous p.His154Pro mutation exhibit a mixed (static and 
motile) ciliary beat pattern. 13   
 
We conducted genetic screening of 86 PCD patients of South Asian (mostly Pakistani) origin, 
detecting that a significant proportion (19%) were homozygous for CCDC103 p.His154Pro 
variant. Amongst these, many were at high risk of being undiagnosed without genetic testing, 
due to normal diagnostic results obtained in PCD investigations. Using electron microscopy 
and protein biochemistry we have sought to further determine the pathogenic nature of the 
p.His154Pro mutation. 
 
 4 
METHODS 
 
Patient selection   
Eighty-six patients of South Asian (primarily Pakistani) descent with clinical signs and 
symptoms of PCD were identified from the UK National PCD Diagnostic and Management 
Services at The Royal Brompton Hospital, London, University Hospital Southampton, 
Birmingham Children’s Hospital, Bradford Royal Infirmary and Leicester General Infirmary. 
1 14  
 
Genetic screening 
All participants gave written informed consent to take part in this study. The protocol was 
approved by the London Bloomsbury Research Ethics Committee (08/H0713/82). High 
throughput screening used next-generation sequencing, either whole exome sequencing 
(WES) or targeted gene panel sequencing. Sequencing and variant identification methods are 
published for whole exome sequencing 12 15 or used custom gene panels (Illumina TruSeq 
Custom Amplicon or Agilent SureSelect Focused Exome (proprietary product) and 
SureSelectXT custom panel design systems) and a standardised variant calling pipeline. 16 
Sanger sequencing was used for variant confirmation and familial segregations. As shown in 
Table 1, of the 16 p.His154Pro cases, this mutation was detected by WES in case #1-6 and #9, 
by use of a ‘clinical exome’ commercial panel in cases #7 and #8 and in cases #10-16 by use 
of custom targeted gene panels containing the known PCD genes and other candidate PCD 
disease genes.  
  
Comparator group 
The comparator patient group consisted of 16 of the 86 individuals tested. This group was 
closely age and gender matched to the CCDC103 p.His154Pro group. All had a dynein arm 
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defect on electron microscopy and all were proven negative for the CCDC103 p.His154Pro 
mutation.  
 
FEV1 measurements  
Spirometry was performed according to American Thoracic Society/European Respiratory 
Society recommendations. 17 Forced expiratory volume in 1 second (FEV1) z-scores were 
calculated using the Global Lungs Initiative parameters. 18 
 
Diagnostic tests 
Screening and diagnostic testing was performed according to the PCD National Service 
protocols. Investigations included nNO, nasal brushing analysed by HSVM for ciliary beat 
frequency and pattern19 and quantitative electron microscopy for ciliary ultrastructure 23 . 
Additional detail on the method is provided in an online data supplement. When results were 
inconclusive or inconsistent, patients were offered repeat testing. 
 
Protein biochemistry on recombinant CCDC103 protein 
Site-directed mutagenesis (QuikChange kit, Agilent Technologies UK Ltd) was used to 
generate the p.His154Pro mutation in an N-terminal His10 tagged H. sapiens CCDC103 
cDNA subcloned into pET16b vector that was synthesized using Escherichia coli codon bias. 
20 Following transformation into E. coli BL21 (DE3), protein expression was induced by 
addition of 2 mM IPTG for two or more hours. Following sonication, His10-tagged proteins 
were dissolved in 8 M urea, then very slowly refolded by their dilution into 1 litre of 20 mM 
Tris.Cl pH8.0 150 mM NaCl. Proteins were then purified by Ni2+-affinity chromatography as 
described previously, using 20 mM Tri pH 8.0, 500 mM NaCl, 250 mM imidazole for elution. 
20 Samples concentrated by ultrafiltration through Amicon Ultra-4 ultrafiltration units were 
subject to gel filtration in a calibrated Superose 6 10/300 column attached to an ÄktaPurifier-
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10 chromatography workstation. 20 The mutant protein was very hard to make and only a little 
was able to be refolded, indeed even the precipitated material was clearly different to the 
wildtype protein being more "sticky". Hence, a lower concentration of the mutant protein is 
apparent in Figure 4. This experiment was done at one concentration (the highest we were 
able to achieve): for wildtype protein this was ~80 ug/ml and for the p.His154Pro protein this 
was ~30 ug/ml.  
 
Statistical analysis 
The CCDC103 p.His154Pro and comparator patient groups were closely matched for age and 
gender. Data was not normally distributed and therefore groups were compared using non-
parametric statistical tests. P<0.05 was considered statistically significant.  
 
 
RESULTS 
 
A PCD-causing mutation CCDC103 p.His154Pro is prevalent in UK individuals of South 
Asian origin with a clinical phenotype of PCD 
 
Next generation sequencing analysis in 86 patients of South Asian descent with suspected 
PCD revealed 16 patients (19%) from 12 independent families homozygous for a previously 
published single base change (NM_001258395.1: c.461A>C) mutation in CCDC103 that 
predicts the amino acid substitution p.His154Pro (Table 1). Consistent with their homozygous 
segregation pattern, all 16 patients were children of consanguineous parents and had dynein 
arm defects or normal ultrastructure.  
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Due to the high frequency of this mutation, we examined whole exome sequence data 
available from 1,542 unaffected parents with similar ethnic backgrounds participating in the 
Born-in-Bradford study, all of UK South Asian, primarily Pakistani heritage. 21 This revealed 
six heterozygous carriers of the CCDC103 p.His154Pro substitution (E. Sheridan, 
unpublished data). The ExAc database 22 of exome sequencing results from 60,706 unrelated 
individuals free from paediatric disease records an allele frequency for p.His154Pro three 
times as high in 8,256 South Asian individuals (0.003) compared to 33,345 North Europeans 
(0.001). No p.His154Pro homozygote individuals were identified in the entire Born-in-
Bradford or ExAc cohorts. 
 
Amongst the sixteen CCDC103 p.His154Pro homozygote PCD patients identified, normal 
diagnostic test results were apparent as highlighted in Table 1. Although PCD was strongly 
suspected in all cases, five of the sixteen patients (case 9 and 13-16 in Table 1) did not receive 
a definitive disease diagnosis until their genotype was confirmed. Remarkably in the case of 
patient 15, this individual had been deemed to not have PCD and was discharged from 
respiratory care. She was re-tested due to her situs inversus and the finding that her brother, 
who remained under clinical suspicion, had this CCDC103 mutation. Thirteen of the 16 
CCDC103 p.His154Pro patients (81%) have situs inversus, including in two families the 
presence of two siblings with situs inversus, and no families without situs inversus. Situs 
inversus is reported to affect approximately 50% patients with PCD with dynein arm defects 2 
and affected 56% of the PCD comparator group in this study (Table 2). 70% of the 
comparator group had situs inversus in their family amongst affected individuals.  
 
FEV1 measurements showed that impact on lung function was similar in the group of 16 
p.His154Pro patients compared to the PCD comparator group (Table 1, Figure 1). The 
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comparator group of 16 South Asian individuals with PCD all had dynein arm deficiency, but 
due to different genetic causes since this group comprised three DNAAF1, 23 two DNAAF3, 24 
two DNAH5, 25 three LRRC6 26 and two ZMYND10 27 cases whilst four were genetically 
undefined. The mean difference for clinical measures between the CCDC103 p.His154Pro 
and comparator groups is presented in Table 2, showing an equivalent age and gender 
composition. Individuals from both groups had symptoms typical of PCD as detailed in 
Supplementary Table 1. There was a higher rate of glue ear and positive sputum microbiology   
and a  lower rate of bronchiectasis in the CCDC103 p.His154Pro group compared to controls, 
but due to the small number of patients and heterogeneous nature of PCD it is difficult to 
interpret the significance of these findings. 
 
PCD caused by the CCDC103 p.His154Pro mutation can be associated with normal 
nasal nitric oxide (nNO) results 
 
We proceeded to retrospectively analyse clinical phenotypes of the sixteen affected South 
Asian patients carrying the homozygous p.His154Pro missense mutation in more detail, as 
presented in Table 1. Of the 16 p.His154Pro patients tested, seven (43%) had normal nNO 
levels, above 77nl/min which is a recommended diagnostic cut off. 28 Of these 7 patients, 
most (patients 5, 7, 11, 12 and 13) were subject to repeat measurements at subsequent clinic 
appointments. Patient 12 displayed persistent values within the normal range up to 5 years 
from the first measurement. Mean nNO was significantly higher than the low levels 
consistently detected in the comparator PCD patient group (Table 2).  
 
PCD caused by the CCDC103 p.His154Pro mutation can be associated with areas of 
normal ciliary beat frequency on high speed video light microscopy  
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High-speed video microscopy revealed that amongst the 16 homozygous p.His154Pro 
individuals, nine (56%) had ciliary beat frequencies within the normal range of 8.5-16.8Hz 
(mean 11.6Hz) (Table 1). The other seven p.His154Pro patients (patients 1-6 and 13) had a 
reduced beat frequency with a mean of 3.9Hz (range 0-7.7Hz), which is more in keeping with 
typical results found for PCD patients and more specifically found for CCDC103 patients 
expressing loss-of-function alleles. 13 29 The comparator group of PCD patients displayed a 
reduced ciliary beat frequency with a mean of 1.3Hz (Table 2), which is similar to the 
reported reduced ciliary beating seen in published PCD cases associated with other causes of 
dynein arm loss. In half the p.His154Pro patients the beat pattern of cilia was completely or 
largely normal in some strips of epithelium (patients 5-7, 9, 10, 12, 15, 16, Table 1) whilst 
static, slow or dyskinetic in others. Some His154Pro patients (7, 10, 16) demonstrated a full 
beat pattern and almost immotile cilia together within the same sample (Supplementary 
videos 1-3). Therefore the motility in p.His154Pro individuals was variable, compared to the 
fully motile cilia of healthy controls (Supplementary video 4) and the completely static cilia 
seen in patients from the comparator group (Supplementary video 5). 
 
PCD caused by the CCDC103 p.His154Pro mutation can be associated with normal 
ultrastructural appearance by electron microscopy  
 
Seven of the 16 CCDC103 p.His154Pro individuals (44%) had a defect of the ciliary inner 
and outer dynein arms demonstrated by transmission electron microscopy (cases 1-7 in Table 
1)  The other nine p.His154Pro individuals (cases 8-16) had TEM that either showed an 
absence of the inner dynein arm, or that was considered normal or inconclusive despite 
extensive interrogation. The spectrum of ultrastructural defects found in p.His154Pro 
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individuals is illustrated with representative examples in Figure 2. Overall, the inner dynein 
arm appeared to be the most affected structure in these cases, with significant retention of 
outer dynein arms. Quantification of these dynein arm defects is shown in Figure 3. Published 
normal range counts from >200 non-PCD respiratory controls are also shown for comparison 
(Figure 3, grey box). Notably, samples from four CCDC103 p.His154Pro patients were 
completely within this normal range, a further two were closer to the normal range than the 
diagnostic range and two although not quantifiable due to small numbers were also reported 
as normal. When a partial defect of the outer dynein arm was seen, an assessment of 
proximity to the epithelial cell surface - as judged by the presence of neighboring microvilli - 
showed that ODA loss typically occurred at the distal end of the cilia, towards the tips.  
 
A summary shown in Table 2 highlights that the majority of CCDC103 p.His154Pro cases 
clearly differed from the non-CCDC103 comparator group, which have a near complete 
absence of both dynein arms. This is highly significant in terms of outer dynein arm loss 
(p<0.05), with only 27% ODA absence in the CCDC103 p.His154Pro cilia compared to 89% 
in the comparator group which carry mutations in other dynein arm-loss associated PCD 
genes. Inner dynein arms were also clearly more retained in CCDC103 p.His154Pro cilia, but 
this difference did not reach statistical significance. The overall relative lack of disturbance to 
dynein arm structures means that CCDC103 p.His154Pro TEM overlaps with that of non PCD 
controls. 
 
Biochemical analysis of the CCDC103 p.His154Pro mutation reveals an abrogation of its 
oligomerisation capacity 
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We conducted gel filtration of purified CCDC103 p.His154Pro protein and compared this to 
the normal protein using previously established methods, 20 to assess the functional viability 
of the mutant form of the protein. The p.His154Pro variant appears to be a highly disruptive 
mutation since the ability of CCDC103 to oligomerize is significantly disrupted by the 
mutation, as shown in the chromatogram (Figure 4). The lack of oligomers that the wildtype 
protein forms (~250 kDa) is however accompanied by a large increase in the void volume of 
the mutant protein. We speculate that this material which is >2 MDa, is aggregated protein, 
rather than organized oligomers. 
 
 
DISCUSSION 
 
We report from genetic screening of a PCD cohort ascertained through UK National PCD 
Services that the CCDC103 c.461A>C; p.His154Pro mutation accounts for disease in 
approximately one fifth of affected individuals in the highly consanguineous South Asian 
PCD community, associated with loss of both the outer and inner dynein arms of cilia. 
Therefore, a significant risk of disease arises from the presence of this important frequent 
mutation which is typically carried in homozygous state, one copy inherited from each parent. 
Direct screening for this specific p.His154Pro mutation in South Asian PCD cases could be an 
economical diagnostic approach. 
 
Despite the relatively high prevalence of CCDC103 p.His154Pro, this mutation is not the sole 
cause of the increased incidence of PCD reported in the British South Asian community. 3 
Our screen also revealed patients in the group of 86 screened that carry causal mutations in a 
number of other genes including CCDC40, DNAAF1, DNAAF3, HEATR2, LRRC6, 
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ZMYND10 and RSPH4A. The CCDC103 p.His154Pro defect is not exclusive to the UK Asian 
community and has also been detected in a patient from an Irish travelling family 30 as well as 
in two North European origin families with PCD from our studies (unpublished data), all of 
whom have dynein arms defects. 
 
This study highlights extensive variability in the diagnostic results for patients carrying 
biallelic CCDC103 p.His154Pro mutations. Normal standard diagnostic test results have led 
to CCDC103 p.His154Pro patients being discharged from the PCD clinic, and in some cases 
the diagnosis of PCD in a CCDC103 p.His154Pro patient was only finally confirmed 
following the genetic test result. Fifteen (94%) patients had situs inversus suggesting 
CCDC103 p.His154Pro patients without situs inversus may be missed either due to lack of 
referral or due to normal diagnostic tests.  
 
The homozygous p.His154Pro positive patients represent an expanded phenotype for PCD, 
since without genetic results many in this group may not have been considered to meet the 
current UK clinical diagnostic criteria for PCD. This would lead to uncertainty for the patient 
and their parents and may result in unnecessary further investigation into the cause of their 
symptoms. One South Asian patient in the comparator group had a TEM phenotype similar to 
that of the CCDC103 p.His154Pro group. This individual also had a nNO level of >77nl/min, 
but a screen for the CCDC103 mutation was negative (Figure 3). This case, along with other 
patients in the UK national diagnostic clinics, suggests that there will be other mutations 
which cause PCD with normal diagnostic results. It is difficult to explain the variability in the 
nasal NO. This variability is temporal within a patient and seen even between siblings. We 
speculate that this may be a broader reflection of ciliary function in the sinuses such that NO 
levels may only be low in CCDC103 p.His154Pro patients when cilia are static (maybe during 
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an infection or other external insult) and may normalise with improved ciliary function. The 
possible reasons why levels might be low in PCD were recently summarized. 31 
 
Interestingly, preservation of some cilia structure and motility in CCDC103 p.His154Pro 
patients is not apparently accompanied by significantly preserved lung function, since the 
FEV1 range in p.His154Pro patients is equivalent to the comparator group and respiratory 
capacity is equally reduced in these individuals. Another missense mutation causing PCD, 
ZMYND10 p.Val16Gly, was similarly found to cause a mixed cilia beat defect with a 
significant degree of retained cilia motility but this is also not yet associated with milder 
disease course.27 In this study, larger numbers of CCDC103 p.His154Pro patients and controls 
should be analysed to confirm this observation and genotype – phenotype relationships could 
be further investigated with more sensitive tests for staging lung disease such as Lung 
Clearance Index, CT scan or radiolabeling methods screening mucociliary clearance rates. 32 
33 Patients with the CCDC103 p.His154Pro mutation represent an interesting cohort for 
targeted pharmocogenetic therapies due to their prevalence and since the dynein components 
required for normal ciliary beating appear to still be present in the patient’s cilia, albeit at 
variable levels.  
 
The finding of nNO levels within the normal range in CCDC103 p.His154Pro patients 
highlights the importance of considering the full clinical history in conjunction with nNO 
testing in patients with suspected PCD. Clinicians should proceed to further testing in cases 
with a high index of clinical suspicion, using the NO test as part of a multidisciplinary 
diagnostic protocol rather than a stand-alone screening test. This is not the first report of 
normal nNO results in patients with PCD. Some patients with RSPH1 mutations are also 
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reported to have levels of NO close to normal and we expect further such cases to be reported 
as the complex genetic landscape of PCD diagnosis is unraveled further. 34  
 
The apparently normal/mixed cilia beat pattern found in half of p.His154Pro cases was 
notably high, but this finding is supported by previous work indicating that this represents a 
hypomorphic allele in cilia function tests. 13 Awareness of these cases is critical when 
assessing diagnostic samples in the laboratory, if the observer inadvertently tends to select 
beating strips for analysis over those that are static when scanning the sample at 5-20 times 
magnification before full analysis with high speed video, thereby inadvertently missing this 
defect when a significant portion of the sample has a normal co-ordinated beat. This places an 
emphasis on diagnostic centres to increase awareness and expertise of the operators when 
assessing nasal biopsies by high-speed video microscopy. HSVM does not quantify the power 
of the ciliary beating, but in cases with a normal stroke and frequency there could be 
weakness in the strength of the beating that might not be detected by any of the current 
diagnostic tests. 
 
In this study, TEM diagnosis often revealed a pattern of intermittent IDA and ODA loss in 
CCDC103 p.His154Pro patients which was distinct from cases of dynein arm absence due to 
mutations in other dynein-loss associated PCD genes e.g. LRRC6, DNAAF1 and ZYMND10. 
The distinction was most significant for ODA retention with CCDC103 p.His154Pro cases, 
with comparatively high levels of preserved ODAs seen in patient’s cilia whilst the IDAs 
were more often missing. Despite analysis of >100 cilia cross sections, usually sufficient for 
diagnosis, the loss of dynein was not always detected by electron microscopy. However, it has 
long been accepted that normal ultrastructure by electron microscopy cannot exclude PCD. 35 
36 Our study appears to confirm in CCDC103 p.His154Pro patients the previous evidence that 
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CCDC103 mutations confer a loss of distal ODAs containing DNAH9, not ODAs in the 
proximal half of the cilia closer to the epithelial surface. 13    
 
This study contributes strong evidence that CCDC103 p.His154Pro is pathogenic rather than a 
benign polymorphism. It is present at very low frequency in the non-PCD population and no 
CCDC103 p.His154Pro homozygote individuals were detected in large scale screening of 
9,798 South Asian and 33,345 North European controls. Also, segregation analysis performed 
where parental samples were available in the affected families studied here showed an 
inheritance pattern fully consistent with recessive disease (Table 1). The CCDC103 protein 
remains poorly characterised but previous studies show that it usually forms dimers and 
higher order oligomers. It is thought to help in generating a high-affinity site on the doublets 
for outer arm assembly, either through direct interactions or indirectly, by modifying the 
underlying microtubule lattice. 20 The oligomerization capacity of CCDC103 is a property of 
the central region of the protein (R.P.K. and S.M.K., unpublished observations) which 
contains a highly conserved RPAP3_C domain that spans residues 96-189 of the protein and 
is predicted to function in protein-protein interactions. 20 The His154 amino acid is located 
within an alpha helix of this RPAP3_C functional domain and substitution of the cyclic side 
chain of proline at this position would enforce a conformation predicted incompatible with 
alpha helical secondary structure. Thus, altering His154 is expected to disrupt the protein’s 
secondary structure and consequently its function. Our current results reveal that the 
His154Pro mutant form retains the ability to dimerize but shows little oligomer formation, 
suggesting that this property is disrupted by the mutation and that CCDC103 may have two 
distinct self-interaction domains. We hypothesise that gene mutations causing instability or 
depletion of CCDC103 protein may make the attachment of the dynein arms more susceptible 
to physical, infective or inflammatory insult. We cannot determine if the presence of normal 
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cilia in our patients is temporal or spatial however, as results appear to vary from one biopsy 
to the next e.g. in TEM data for case 11, 12, 15 and 16 in Table 1; cell culture and repeating 
investigations may be useful in these cases.   
 
It can often be difficult to make or exclude a diagnosis of PCD due to poor sensitivity of 
electron microscopy and genetic testing and the poor specificity of nasal nitric oxide 
measurement. 37 Currently, diagnosis using multiple tests is recommended. These tests are 
often complex and require specialist equipment and skills to interpret. Consequently, several 
patients continue to have an indeterminate diagnosis. Awareness of variants such as 
CCDC103 p.His154Pro may allow targeted gene screening in patients with an indeterminate 
diagnosis. 
 
In conclusion, the CCDC103 p.His154Pro variant is prevalent in the UK South Asian 
community and likely to be found in South Asian patients worldwide. This patient group 
should therefore undergo genetic testing for c.461A>C, especially if (partial) dynein arm 
absence is suspected. These patients frequently present a diagnostic dilemma, due to 
inconclusive results of multiple clinical diagnostic tests. This study expands the diagnostic 
phenotype which we consider to be PCD, since in some cases pathology-based tests can be 
equivocal as the cilia can beat at least partially in a co-ordinated manner, at the correct speed 
and may appear structurally normal. PCD is widely understood to be an underdiagnosed 
condition and this appears to be the case for CCDC103 p.His154Pro patients, who 
demonstrate a high level of situs inversus probably indicative of a lack of recognition making 
their diagnosis liable to be missed. 38 We anticipate that studies such as this, in combination 
with easier access to high throughput and economically achievable genetic screening, should 
greatly increase disease recognition and understanding. We have highlighted the importance 
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of multidisciplinary testing, repeat testing and genotyping in patients with a highly suggestive 
history for PCD.  
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Demographics Symptoms  
  
Diagnostic test results 
  
ID Sex 
Age 
(yrs) 
Age 
diag 
(yrs) 
Family 
History 
FEV1 z-
score 
Main Symptoms Situs 
Nasal 
NO 
(nl/min) 
CBF 
(Hz) 
Ciliary beat pattern 
Electron 
microscopy 
(1st 
brushing) 
Electron 
microscopy 
(repeat 
brushing) 
Genetics: 
sequencing 
protocol and 
segregations 
1 M 7 7 No -3.45 Chronic cough, developmental delay SI ND 0 
Immotile 
IDA +ODA IDA +ODA 
CM Watson et al. 
2014 
2 M 4 1 Sib 3 -2.25 Nasal discharge SI 1 0.95 
Mostly immotile with occasional 
residual movement 
IDA +ODA IDA +ODA 
CM Watson et al. 
2014 
3 M 12 10 Sib 2 -2.75 
Neonatal respiratory distress, nasal 
discharge 
SS 11 2.9 
Mostly immotile with occasional 
residual movement 
IDA +ODA IDA +ODA 
CM Watson et al. 
2014 
4 M 13 <1 No ND 
Neonatal respiratory distress, Gilbert 
syndrome, epilepsy 
SI 7 5.9 
Mostly immotile with occasional 
residual movement 
IDA +ODA IDA +ODA 
CM Watson et al. 
2014 
5 M 13 6 Sib 6 -1.52 Recurrent chest infections SI 87 5.79 
Normal ciliary beat pattern 
reduced frequency 
IDA +ODA IDA +ODA WESP 
6 F 15 4 Sib 5 -0.61 
Recurrent chest infections, Eustachian 
tube dysfunction, nasal discharge 
SS 43 7.66 
Normal ciliary beat pattern 
reduced frequency 
IDA +ODA IDA +ODA WESP 
7 F 18 9 No -1.58 
Recurrent chest infections, nasal 
discharge, bilateral glue ear 
SI 111 10.6 
Mixed Sample 1: normal ciliary 
beat pattern sample 2: Immotile 
IDA +ODA IDA +ODA 
Illumina TruSeq 
custom gene panel M 
8 M 9 6 No -0.08 
Wet cough, recurrent chest infections, 
conductive hearing loss 
SI 57 8.8 Dyskinesia IDA IDA 
Agilent SureSelect 
Focused Exome P 
9 F 7 7 CHD 0.43 Chronic cough SI 33 10.9 Normal ciliary beat pattern Normal ND 
CM Watson et al. 
2014 
10 M 10 <1 
Sib 11 
& 12 
-1.32 
Neonatal respiratory distress, nasal 
discharge 
SI 26 11.5 
Mixed: Normal  areas, immotile 
areas, dyskinetic areas 
Normal Normal 
Illumina TruSeq 
custom gene panel B 
11 F 21 10 
Sib 10 
& 12 
ND 
Recurrent chest infections, asthma, 
persistent collapse of right lower lobe 
SI 293 8.5 
Mixed: Mostly reduced forward and 
recovery stroke 
IDA Normal 
Illumina TruSeq 
custom gene panel B 
12 M 13 <1 
Sib 10 
&11 
-1.24 
Neonatal respiratory distress, nasal 
discharge 
SS 214 16.3 Normal ciliary beat pattern IDA Normal 
Illumina TruSeq 
custom gene panel B 
13 F 29 29 No ND Bronchiectasis, infertility SI 239 4.31 
Mixed: Mostly reduced forward and 
recovery stroke. Static patches 
Normal Insufficient 
Agilent 
SureSelectXT B 
Ciliome_651 
14 F 1 1 No ND 
Neonatal respiratory distress, nasal 
discharge, wet cough 
SI ND 16.76 Dyskinesia Normal Inconclusive 
Agil nt 
SureSelectXT 
Ciliome_651 
15 F 21 21 Sib 16 ND 
Recurrent chest infections in 
childhood. No ear, chest or nasal 
symptoms in adulthood 
SI 151 10.9 Normal ciliary beat pattern IDA Normal 
Agil nt 
SureSelectXT M 
Ciliome_651 
16 M 18 18 Sib 15 ND 
Sensory neural hearing impairment, 
recurrent chest infections, chronic 
nasal congestion and rhinitis 
SI 276 9.9 
Mixed. 80% normal ciliary beat 
pattern. 20% immotile cilia on 
strips. 
IDA Normal 
Agilent 
SureSelectXT 
Ciliome_651 M 
Table 1.Clinical history of CCDC103 p.His154Pro cases summarising diagnostic investigations Normal test results are highlighted in bold. 
Age diag, age diagnosis confirmed; SI, situs inversus; SS, situs solitus; NO, nitric oxide; CBF, ciliary beat frequency; IDA, inner dynein arm; 
ODA, outer dynein arm; ND, not done. Segregation analysis indicated by M (mother is carrier), P (father is carrier) or B (both parents carriers), 
unaffected siblings have not been tested.
 1 
Clinical features N CCDC103 p.His154Pro N Comparator group 
Age (mean SD) 16 11.8 (4.8) 16 11.9 (8.8) 
Gender (% Male) 16 67% 16 63% 
Nasal Nitric Oxide (nl/min) 14 63 (63) 9 12 (7)** 
Ciliary beat frequency (Hz) 16 7.5 (4.7) 16 1.3 (3.6)** 
% Cross sections with  IDA absent on TEM 13 45% (24) 16 63% (30) 
% Cross sections with  ODA absent on TEM 13 19% (12) 16 89% (20)** 
FEV1 z score (median IQR) 10 -1.4 (-0.8, -2.1) 13 -1.8 (-1.5, -2.1) 
Situs Inversus 16 81% 16 56% 
 
Table 2. Comparison of mean values of clinical tests obtain in CCDC103 p.His154Pro 
cases versus a comparator group  The CCDC103 p.His154Pro cases are described in Table 
1 and the comparator group are South Asian origin CCDC103 p.His154Pro-negative cases 
with a confirmed absent dynein arms defect and genetic results as described in the main text. 
We only show TEM data for patients in whom more than 100 cilia were counted. Data shown 
as the mean, with standard deviation shown in brackets (StDev) unless otherwise stated. ** 
p<0.005.  
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FIGURE LEGENDS 
Figure 1.Comparison of predicted FEV1 in CCDC103 p.His154Pro cases versus a 
comparator group 
The CCDC103 p.His154Pro cases are described in Table 1 and the comparator group are 
South Asian origin CCDC103 p.His154Pro-negative cases with a confirmed absent dynein 
arms defect. Mutations carried by the comparator group are in DNAAF1 (3 cases), DNAAF3 
(2 cases), DNAH5 (2 cases), LRRC6 (3 cases), ZMYND10 (2 cases), whilst 4 cases were 
genetically undefined. 
 
Figure 2. Transmission electron microscopy of CCDC103 p.His154Pro patients 
Representative cilia cross sections from CCDC103 p.His154Pro patients show within the 
same micrograph (A) absent outer and partially absent inner dynein arms and (B) presence of 
outer dynein arms only and presence of both inner and outer dynein arms. (C) Inset shows 
presence of outer but not inner dynein arms. Black arrows indicate example outer dynein 
arms. White arrows indicate inner dynein arms. Scale bar, 100 nm. 
 
Figure 3. Quantitative transmission electron microscopy survey of inner and outer 
dynein arm loss in CCDC103 p.His154Pro patients versus a comparator group 
By surveying >100 cross sections in each patient sample we performed quantitative electron 
microscopy to determine the percentage of arm defects in cilia from individuals homozygous 
for the hypomorphic p.His154Pro CCDC103 mutation. Note that quantitative plots have only 
been included within this graph if more than 100 cilia were counted and that all data has been 
collected at a single centre to ensure uniform results; data collected for one sample from a 
separate centre was therefore excluded. Red diamonds and triangles indicate results from 16 
CCDC103 p.His154Pro homozygote PCD patients, where triangles indicates the result of 4 
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repeat nasal brushings performed on patients marked by a diamond. The comparator group of 
16 individuals with PCD, indicated by other symbols as shown, consists of 3 cases with 
DNAAF1 mutations (open diamonds), 2 DNAAF3 (black squares), 2 DNAH5 (dark blue 
diamonds), 3 LRRC6 (2 as light blue diamonds, 1 contained within the filled purple circle), 2 
ZMYND10 (contained within the filled purple circle) and 4 cases in whom no mutations in 
known genes could be identified (grey squares). Six CCDC103 p.His154Pro samples (27%) 
of p.His154Pro samples showed complete lack of both outer and inner dynein arms 
comparable to other gene mutations in the graph (purple circle). The grey shaded area 
represents normal range counts from >200 non PCD respiratory controls. Four CCDC103 
p.His154Pro patients had counts within this normal range (one is a repeat sample (triangle) 
which showed similar data). Individuals with CCDC103 p.His154Pro mutation have a trend 
towards a distinctive pattern of partial loss of dynein arms that diverges from total dynein arm 
loss in the comparator group.  
 
Figure 4. CCDC103 p.His154Pro oligomerisation capacity Chromatograms of wildtype 
(red trace) and His154Pro (green trace) CCDC103 native proteins separated in a calibrated 
Superose 6 10/300 gel filtration column.  The data is plotted as absorbance at 280 nm (in 
mAU) against elution volume (ml). Both proteins show strong dimer peaks at ~60 kDa.  
However, only the wildtype form generates a series of higher-order oligomers with an 
approximate mass of ~250 kDa. Aggregated material (>2 MDa) eluted in the void volume. 
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 SUPPLEMENTARY VIDEOS 
 
Supplementary video 1 
HSVM of p.His154Pro homozygote patient 10 captures fully beating cilia 
 
Supplementary video 2 
HSVM of p.His154Pro homozygote patient 10 captures mixed dyskinetic and faintly 
moving/immotile cilia   
 
Supplementary video 3 
HSVM of p.His154Pro homozygote patient 16 captures mixed beat pattern (immotile 
and beating) 
 
Supplementary video 4 
HSVM of patient carrying ZMYND10 mutations (static) from comparator group 
 
Supplementary video 5 
HSVM of health control (normal beat) 
 
 
